
Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Mendus
7,6
SEK
−1,94 %
IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Alle 1K seuraajaa
−1,94%
−7,32%
−2,58%
−20%
−0,26%
−14,51%
−86,84%
−95,83%
−94,26%
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Lue lisääMarkkina-arvo
382,73 milj. SEK
Vaihto
104,51 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
6.5.
2025
Yhtiökokous '25
6.5.
2025
Osavuosikatsaus Q1'25
22.8.
2025
Osavuosikatsaus Q2'25
NäytäKaikki sisältötyypit

Mendus AB Year-end Report 2024
Invitation to presentation of Mendus’ year-end report for 2024
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Mendus to participate in investor and industry conferences in February
Mendus to participate in several investor and industry conferences in January
FDA and EMA feedback endorses vididencel registration trial preparations
Mendus announces termination by Institut Bergonié of the collaboration agreement to study ilixadencel in soft tissue sarcomas
Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancer
Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel

Mendus: We are discontinuing coverage

Lääkekehityksen viranomaissäätely
Redeye: Mendus Q3 2024 - Minor catalysts in Q4 2024e, CADENCE in focus

Mendus Q3'24: Building basis for a pivotal trial

Mendus, Audiocast with teleconference, Q3'24
Mendus Announces Nomination Committee for the 2025 Annual General Meeting
Mendus AB Interim Report January – September 2024
Mendus to present preclinical data supporting the combination potential of ilixadencel with the immune checkpoint inhibitor avelumab at SITC 2024
Mendus to present multiple abstracts at ASH 2024, including survival update of ADVANCE II trial with lead program vididencel in AML
